The University of Vermont Health Network

CILcare is a biotechnology company focused on developing innovative drug solutions for hearing and ear disorders. Utilizing advanced auditory sciences, the company aims to enhance the early definition, detection, and treatment of synaptopathy associated with neurocognitive and inflammatory diseases. By leveraging its technology, CILcare seeks to equip healthcare professionals with effective treatment options for patients suffering from various ear diseases, thereby improving patient outcomes in the field of auditory health.

THEYA Healthcare is a multi-award-winning medical device company that specializes in the design and manufacture of innovative post-surgery garments, particularly for women undergoing breast cancer treatment and other cosmetic surgeries. Founded by Ciara Donlon in 2015, the company emerged from a recognized need for comfortable and feminine underwear that catered to the specific requirements of post-operative patients. Theya Healthcare's flagship product line features bras made from a unique bamboo fabric that is scientifically proven to be antibacterial, highly absorbent, and effective at wicking moisture away from the skin. Clinical trials conducted in Dublin demonstrated that patients wearing Theya Healthcare products experienced significant improvements in body image and health status, along with reduced pain and discomfort compared to competing products. Since its inception, the company has garnered numerous accolades, highlighting its commitment to enhancing the recovery experience for women after surgery.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

BioFactura, Inc. is a biotechnology company based in Frederick, Maryland, focused on the development and manufacturing of high-value biosimilars, biodefense medical countermeasures, and novel drugs tailored to client specifications. Established in 2001, BioFactura utilizes its proprietary StableFast Biomanufacturing Platform, which allows for the rapid generation of stable cell lines, to enhance the efficiency and quality of biopharmaceutical production. This innovative platform is characterized by its chemically-defined, serum- and cholesterol-free production medium, modular expression vectors, and a proprietary growth supplement, enabling the development of clonal production cell lines capable of yielding significant quantities of product in a short timeframe. In addition to its core manufacturing capabilities, BioFactura offers a range of services including expression system development, purification process development, and custom analytical development, alongside research and consulting services.